[Clinical aspects of type-C cirrhosis of liver--diagnosis, clinical course, treatment and prognosis].
Yamada
Goutarou
G
Department of Internal Medicine, Center for Liver Disease, Kawasaki Hospital, Kawasaki Medical School.
D000998:Antiviral Agents / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000517:prevention & control; D003545:Cysteine / Q000627:therapeutic use; D018450:Disease Progression; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005355:Fibrosis; D005998:Glycine / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000473:pathology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D008113:Liver Neoplasms / Q000209:etiology / Q000517:prevention & control; D009828:Oleanolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011379:Prognosis; D012254:Ribavirin / Q000008:administration & dosage; D012306:Risk; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D000998:Antiviral Agents; D004338:Drug Combinations; D012254:Ribavirin; D009828:Oleanolic Acid; C009781:neominophagen C; D014580:Ursodeoxycholic Acid; D007372:Interferons; D003545:Cysteine; D005998:Glycine